Menu
In this project of the Center for Health Consumer Ethics and Evidencebased Gender Health Care, a systematic review on the adverse effects of cyproterone acetate is being prepared.
The aim of this review is to evaluate the adverse effects of cyproterone acetate (CPA) treatment in the main indications.
There is a wide range of indications for the administration of CPA, including contraception. However, there are significant adverse effects associated with the use of CPA. Common adverse effects include depressed mood and restlessness, change in body weight, shortness of breath, hepatotoxicity, discomfort or enlargement of the breasts, flushing, sweating and fatigue. A rare side effect is the occurrence of skin rashes. Allergic reactions, tender lumps in the breasts and lactation occur rarely.
The aim of this Systematic Review is to gain more insight into the risks associated with treatment with CPA.
We will include randomized controlled trials (RCTs) involving adult consumers (aged 18 years and over) treated with CPA for their particular indication.
We will include all methods of use that are being developed. We do not impose any limits on language or year of publication.
We will search the following electronic databases for relevant studies: JBI EBP Database, Cochrane Central Register of Controlled Trials (CENTRAL), Medline via PubMeD, Embase, Web of Science, CINAHL, PsycINFO, PSYNDEX, Scopus and Science Direct.
We successfully tested screening methods for abstracts and titles.
Two review authors will independently search the titles and abstracts of the datasets to generate a list of potential studies to be included in the final review. Subsequently, the same authors will examine the full texts. Any conflicts between the decisions to include or exclude a study will be resolved by consensus or with the assistance of a third reviewer.